Clinical Trial

Pre-Pilot (R61) WINGS+++: mHealth to Improve MOUD Uptake in Women Experiencing Intimate Partner Violence and PTSD

Enrolling by Invitation
View on ClinicalTrials.gov →
Summary
The goal of this pre-pilot for the clinical trial is to develop a mobile health (mHealth) program called WINGS+++ can help women with opioid use disorder or other substance use disorders who have experienced intimate partner violence. The pre-pilot study will take place in Orange County, New York with n=7 women. . The main questions it aims to answer are: 1. Does WINGS+++ lower non-prescription opioid and other drug use in women? 2. Does WINGS+++ help connect women to treatment for substance use, intimate partner violence, and post-traumatic stress disorder (PTSD)? Researchers will compare WINGS+++ to standard care to see if WINGS+++ works better to lower drug use and link women to helpful services. WINGS+++ is a 3-session program on a mobile device that: * Screens for intimate partner violence, PTSD, and substance use * Offers brief support and referrals based on each woman's needs and preferences * Connects women to a peer navigator who helps link them to services Participants will: * Take part in only the WINGS+++ program for the pre-pilot * Answer survey questions about drug use, intimate partner violence, and PTSD symptoms * Provide biological samples (such as urine or hair) to check for drug use * Share information about the services they have used
Protocol Amendment History 1 change
critical Trial status changed: Not Yet Recruiting → Enrolling by Invitation 2026-07-21
Trial Details
NCT Number NCT07665502
Lead Sponsor Dawn A. Goddard-Eckrich
Collaborators: National Institute on Drug Abuse (NIDA), City University of New York, University of Pennsylvania
Conditions Opioid-Related Disorders, Substance-Related Disorders, Intimate Partner Violence (IPV), Stress Disorders, Post-Traumatic, Domestic Violence, Medication for Opioid Use Disorder (MOUD), Post Traumatic Stress Disorder PTSD
Enrollment 7 participants
Start Date 2026-04-21
Primary Completion 2027-08-27 (estimated)
Study Completion 2027-08-31 (estimated)
Updated on ClinicalTrials.gov 2026-07-28